■HK inno.N announced on the 8th that it has received approval from the Ministry of Food and Drug Safety for the domestic clinical phase 3 trial plan of ‘IN-B00009’ (ingredient name ecklon glutide), which is being developed as an obesity treatment. The trial will evaluate the safety and effectiveness of administering IN-B00009 once a week to adult obesity patients without diabetes. Previously, a clinical phase 2 study targeting obese patients was conducted in Australia and New Zealand. The study confirmed safety and weight loss effects when administered for 26 weeks.
■Onconic Therapeutics noted on the 8th that it will present the clinical trial of the next-generation dual-targeted anticancer drug candidate ‘Nesupali’ at the American Society of Clinical Oncology (ASCO) held in Chicago, USA. Nesupali has been designated as an orphan drug for pancreatic cancer by the U.S. Food and Drug Administration (FDA). The company will present the trial currently being conducted in the 1b stage of a 1b/2 clinical trial targeting metastatic pancreatic cancer.
■GI Innovation's affiliate GI Biome announced on the 8th that it has received approval from the Ministry of Food and Drug Safety for the clinical phase 2a trial plan of the microbiome therapy ‘GB-X01’. GB-X01 is a single live microorganism drug candidate. It has antitumor effects and enhances barrier function when the intestines are damaged. Previously, in clinical phase 1, it showed improvement in low anterior resection syndrome when taken in high doses.
■SillaJen announced on the 8th that it will present research on the anticancer drug BAL0891 at the European Hematology Association (EHA) conference in Milan, Italy. The EHA is regarded as one of the two major hematologic oncology conferences along with the American Society of Hematology (ASH). The company will present an overview of the BAL0891 acute myeloid leukemia clinical study approved by the U.S. Food and Drug Administration.
■JaySis Medical announced on the 8th that it recently participated in the American Society for Laser Medicine and Surgery (ASLMS) held in Florida, USA. JaySis Medical is establishing a U.S. subsidiary to officially enter the U.S. aesthetic medical device market. The company showcased its representative products, Densiti, Lineage, and Smooth Cool, and introduced technology utilizing high-frequency energy.
■HITS, an artificial intelligence (AI) drug development platform corporation, announced on the 29th that it has formed a strategic partnership with eMolecules, a compound corporation. The two companies plan to shorten the early stages of drug development using AI technology and compounds. They will assist in research and development (R&D) from the identification of new drug candidates to synthesis.